Supplementary Balance Sheet Information

6 Months Ended

Jun. 30, 2023

Balance Sheet Related Disclosures [Abstract]

Note 5 – Supplementary Balance Sheet Information

Property and equipment consist of the following (in thousands):



	June 30, 2023			December 31, 2022
Lab equipment	$	6,038		$	6,035
Leasehold improvements		2,365			2,365
Computer equipment		1,075			749
Furniture and fixtures		349			349
Software		325			324
Vehicles		97			97
Construction in process		16,338			2,947
		26,587			12,866
Less accumulated depreciation		(7,591	)		(7,018	)
Total property and equipment, net	$	18,996		$	5,848

Depreciation expense for the three and six months ended June 30, 2023 was $0.3 million and $0.6 million, respectively, compared to $0.4 million and $0.8 million for the three and six months ended June 30, 2022, respectively.

Intangible assets, excluding goodwill, consist of the following (in thousands):


	June 30, 2023							December 31, 2022
	Cost		Accumulated Amortization			Net Carrying Value		Cost		Accumulated Amortization			Net Carrying Value
Intangible assets subject to amortization
Patents	$	1,945	$	(699	)	$	1,246	$	1,880	$	(647	)	$	1,233
Purchased technology		16,900		(9,389	)		7,511		16,900		(8,450	)		8,450
Intangible assets not subject to amortization
Trademarks		114		—			114		114		—			114
Total	$	18,959	$	(10,088	)	$	8,871	$	18,894	$	(9,097	)	$	9,797

Amortization expense related to definite-lived intangible assets was $0.5 million and $1.0 million for both the three and six months ended June 30, 2023 and 2022, respectively.

Future estimated amortization expense of intangible assets is (in thousands):


	As of June 30, 2023
Remainder of 2023	$	990
2024		1,973
2025		1,967
2026		1,953
2027		1,003
2028 and thereafter		871
Total	$	8,757

Accrued liabilities consist of the following (in thousands):



	June 30, 2023		December 31, 2022
Compensation related accruals	$	3,913	$	4,671
Accrued clinical trial expense		1,270		1,232
Other expenses		1,798		2,315
Total accrued liabilities	$	6,981	$	8,218